Cite
MLA Citation
J Vest et al.. “P.025 APOLLO, a phase 3 study of patisiran for the treatment of hereditary transthyretin amyloidosis (hATTR): 18-month safety and efficacy in subgroup with cardiac involvement.” Canadian journal of neurological sciences, vol. 46, n.d., p. S20. http://access.bl.uk/ark:/81055/vdc_100101981302.0x000032